Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
Adulterated cannabis
CB1 cannabinoid receptor bioassay
Harm reduction
New psychoactive substances (NPS)
Synthetic cannabinoid receptor agonists (SCRAs)
Untargeted screening
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
23
01
2024
accepted:
18
06
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
Since late 2019, fortification of 'regular' cannabis plant material with synthetic cannabinoid receptor agonists (SCRAs) has become a notable phenomenon on the drug market. As many SCRAs pose a higher health risk than genuine cannabis, recognizing SCRA-adulterated cannabis is important from a harm reduction perspective. However, this is not always an easy task as adulterated cannabis may only be distinguished from genuine cannabis by dedicated, often expensive and time-consuming analytical techniques. In addition, the dynamic nature of the SCRA market renders identification of fortified samples a challenging task. Therefore, we established and applied an in vitro cannabinoid receptor 1 (CB The assay principle relies on the functional complementation of a split-nanoluciferase following recruitment of β-arrestin 2 to activated CB The bioassay successfully detected all samples of a set (n = 24) of analytically confirmed authentic Spice products, additionally providing relevant information on the 'strength' of a preparation and whether different samples may have originated from separate batches or possibly the same production batch. Finally, the methodology was applied to assess the occurrence of SCRA adulteration in a large set (n = 252) of herbal materials collected at an international dance festival. This did not reveal any positives, i.e. there were no samples that yielded a relevant CB In summary, we established SCRA screening of herbal materials as a new application for the activity-based CB
Sections du résumé
BACKGROUND
BACKGROUND
Since late 2019, fortification of 'regular' cannabis plant material with synthetic cannabinoid receptor agonists (SCRAs) has become a notable phenomenon on the drug market. As many SCRAs pose a higher health risk than genuine cannabis, recognizing SCRA-adulterated cannabis is important from a harm reduction perspective. However, this is not always an easy task as adulterated cannabis may only be distinguished from genuine cannabis by dedicated, often expensive and time-consuming analytical techniques. In addition, the dynamic nature of the SCRA market renders identification of fortified samples a challenging task. Therefore, we established and applied an in vitro cannabinoid receptor 1 (CB
METHODS
METHODS
The assay principle relies on the functional complementation of a split-nanoluciferase following recruitment of β-arrestin 2 to activated CB
RESULTS
RESULTS
The bioassay successfully detected all samples of a set (n = 24) of analytically confirmed authentic Spice products, additionally providing relevant information on the 'strength' of a preparation and whether different samples may have originated from separate batches or possibly the same production batch. Finally, the methodology was applied to assess the occurrence of SCRA adulteration in a large set (n = 252) of herbal materials collected at an international dance festival. This did not reveal any positives, i.e. there were no samples that yielded a relevant CB
CONCLUSION
CONCLUSIONS
In summary, we established SCRA screening of herbal materials as a new application for the activity-based CB
Identifiants
pubmed: 38951904
doi: 10.1186/s12954-024-01044-4
pii: 10.1186/s12954-024-01044-4
doi:
Substances chimiques
Cannabinoid Receptor Agonists
0
Receptor, Cannabinoid, CB1
0
Cannabinoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127Subventions
Organisme : The Bijzonder Onderzoeksfonds (BOF) of Ghent University
ID : BOF21/DOC/248
Informations de copyright
© 2024. The Author(s).
Références
EMCDDA. Thematic papers: understanding the ‘Spice’ phenomenon. Luxembourg: Publications Office of the European Union; 2009.
EMCDDA. Synthetic cannabinoids in Europe - a review. Luxembourg: Publications Office of the European Union; 2021.
EMCDDA. New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU early warning system (June 2022). Luxembourg: Publications Office of the European Union; 2022.
Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58:315–48.
doi: 10.1016/S0301-0082(98)00087-2
pubmed: 10368032
Lapoint J, James L, Moran C, Nelson L, Hoffman R, Moran J. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila). 2011;49:760–4.
doi: 10.3109/15563650.2011.609822
pubmed: 21970775
Abouchedid R, Hudson S, Thurtle N, Yamamoto T, Ho JH, Bailey G, Wood M, Sadones N, Stove CP, Dines A, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin Toxicol (Phila). 2017;55:338–45.
doi: 10.1080/15563650.2017.1287373
pubmed: 28421836
Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128:e1622–27.
doi: 10.1542/peds.2010-3823
pubmed: 22065271
Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011;117:152–7.
doi: 10.1016/j.drugalcdep.2011.01.012
pubmed: 21316162
Müller H, Huttner HB, Köhrmann M, Wielopolski JE, Kornhuber J, Sperling W. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry. 2010;43:152–3.
doi: 10.1055/s-0029-1243252
pubmed: 20127596
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
doi: 10.1016/j.drugalcdep.2014.08.005
pubmed: 25220897
Mohr ALA, Logan BK, Fogarty MF, Krotulski AJ, Papsun DM, Kacinko SL, Huestis MA, Ropero-Miller JD. Reports of adverse events Associated with Use of Novel psychoactive substances, 2017–2020: a review. J Anal Toxicol. 2022;46:e116–85.
doi: 10.1093/jat/bkac023
pubmed: 35445267
pmcid: 9282356
Debruyne D, Le Boisselier R. Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Subst Abuse Rehabil. 2015;6:113–29.
doi: 10.2147/SAR.S73586
pubmed: 26543389
pmcid: 4622447
Staatsblad België: Koninklijk besluit houdende regeling van verdovende middelen en psychotrope stoffen. Federale Overheidsdienst Volksgezondheid. Veiligheid van de voedselketen en leefmilieu; 2017.
Musah RA, Domin MA, Walling MA, Shepard JR. Rapid identification of synthetic cannabinoids in herbal samples via direct analysis in real time mass spectrometry. Rapid Commun Mass Spectrom. 2012;26:1109–14.
doi: 10.1002/rcm.6205
pubmed: 22467461
Krotulski AJ, Varnum SJ, Logan BK. Sample Mining and Data Mining: Combined Real-Time and Retrospective approaches for the identification of emerging Novel psychoactive substances. J Forensic Sci. 2020;65:550–62.
doi: 10.1111/1556-4029.14184
pubmed: 31498433
Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010;197:157–62.
doi: 10.1016/j.toxlet.2010.06.002
pubmed: 20566335
Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, Wood DM. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in herbal high products. J Anal Toxicol. 2010;34:252–60.
doi: 10.1093/jat/34.5.252
pubmed: 20529459
Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;39:234–43.
doi: 10.1016/j.pnpbp.2012.04.017
Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull. 2009;57:439–41.
doi: 10.1248/cpb.57.439
Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N. Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44:832–7.
doi: 10.1002/jms.1558
pubmed: 19189348
Schneir AB, Cullen J, Ly BT. Spice girls: synthetic cannabinoid intoxication. J Emerg Med. 2011;40:296–9.
doi: 10.1016/j.jemermed.2010.10.014
pubmed: 21167669
EMCDDA. Low-THC cannabis products in Europe. Luxembourg: Publications Office of the European Union; 2020.
Schläpfer M, Bissig C, Bogdal C. ‘Synthetische Cannabimimetika auf Industriehanfblüten. Ein gefährliches Aufeinandertreffen zweier bekannter Phänomene’. In Kriminalistik. 2020;7:433–35.
Gerace E, Seganti F, Di Corcia D, Vincenti M, Salomone A. GC-MS identification and quantification of the synthetic cannabinoid MDMB-4en- PINACA in Cannabis-derived material seized in the Turin Metropolitan Area (Italy). Curr Pharm Des. 2022;28:2618–21.
doi: 10.2174/1381612828666220603142859
pubmed: 35658890
Holt AK, Karin KN, Butler SN, Ferreira AR, Krotulski AJ, Poklis JL, Peace MR. Cannabinoid-based vaping products and supplement formulations reported by consumers to precipitate adverse effects. Drug Test Anal. 2023;15:1067–76.
doi: 10.1002/dta.3253
pubmed: 35347865
Monti MC, Zeugin J, Koch K, Milenkovic N, Scheurer E, Mercer-Chalmers-Bender K. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: results from drug checking services. Drug Test Anal. 2022;14:1026–39.
doi: 10.1002/dta.3220
pubmed: 34997693
pmcid: 9305195
Oomen PE, Schori D, Tögel-Lins K, Acreman D, Chenorhokian S, Luf A, Karden A, Paulos C, Fornero E, Gerace E, et al. Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services. Int J Drug Policy. 2022;100:103493.
doi: 10.1016/j.drugpo.2021.103493
pubmed: 34687992
Cannaert A, Storme J, Franz F, Auwärter V, Stove CP. Detection and activity profiling of Synthetic cannabinoids and their metabolites with a newly developed Bioassay. Anal Chem. 2016;88:11476–85.
doi: 10.1021/acs.analchem.6b02600
pubmed: 27779402
Cannaert A, Franz F, Auwärter V, Stove CP. Activity-based detection of consumption of Synthetic cannabinoids in authentic urine samples using a stable cannabinoid reporter system. Anal Chem. 2017;89:9527–36.
doi: 10.1021/acs.analchem.7b02552
pubmed: 28771321
Cannaert A, Storme J, Hess C, Auwärter V, Wille SMR, Stove CP. Activity-based detection of cannabinoids in serum and plasma samples. Clin Chem. 2018;64:918–26.
doi: 10.1373/clinchem.2017.285361
pubmed: 29559524
Janssens LK, Boeckaerts D, Hudson S, Morozova D, Cannaert A, Wood DM, Wolfe C, De Baets B, Stock M, Dargan PI, Stove CP. Machine learning to assist in Large-Scale, activity-based synthetic cannabinoid receptor agonist screening of serum samples. Clin Chem. 2022;68:906–16.
doi: 10.1093/clinchem/hvac027
pubmed: 35266984
Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, Butler BL, Binkowski BF, Machleidt T, Kirkland TA, et al. NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in cells. ACS Chem Biol. 2016;11:400–8.
doi: 10.1021/acschembio.5b00753
pubmed: 26569370
Thoren KL, Colby JM, Shugarts SB, Wu AH, Lynch KL. Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening. Clin Chem. 2016;62:170–8.
doi: 10.1373/clinchem.2015.241315
pubmed: 26453698
Blanckaert P, Cannaert A, Van Uytfanghe K, Hulpia F, Deconinck E, Van Calenbergh S, Stove C. Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene. Drug Test Anal. 2020;12:422–30.
doi: 10.1002/dta.2738
pubmed: 31743619
Wouters E, Walraed J, Robertson MJ, Meyrath M, Szpakowska M, Chevigné A, Skiniotis G, Stove C. Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. ACS Pharmacol Transl Sci. 2020;3:285–95.
doi: 10.1021/acsptsci.9b00069
pubmed: 32296768
Grafinger KE, Cannaert A, Ametovski A, Sparkes E, Cairns E, Banister SD, Auwärter V, Stove CP. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB(1) receptor activation assays-part II: structure activity relationship assessment via a β-arrestin recruitment assay. Drug Test Anal. 2021;13:1402–11.
doi: 10.1002/dta.3035
pubmed: 33769699
Deventer MH, Van Uytfanghe K, Vinckier IMJ, Reniero F, Guillou C, Stove CP. A new cannabinoid receptor 1 selective agonist evading the 2021 China ban: ADB-FUBIATA. Drug Test Anal. 2022;14:1639–44.
doi: 10.1002/dta.3285
pubmed: 35570246
Noble C, Cannaert A, Linnet K, Stove CP. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors. Drug Test Anal. 2019;11:501–11.
doi: 10.1002/dta.2517
pubmed: 30280499
Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, Deventer MH, Ellison R, Boyd R, Martin LJ, et al. Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Med Chem. 2022;13:156–74.
doi: 10.1039/D1MD00242B
pubmed: 35308023
Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, Ellison R, Gerona R, Banister SD, Stove CP. Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chem Neurosci. 2020;11:4434–46.
Guest E. DEA Dosing studies: Investigation of JWH-018 concentration in spice packages. Emerging trends in synthetic drugs workshop presentation slides. National Institiute of Standards and Technology: Drug Enforcement Administration; 2013.
Wang M, Wang YH, Avula B, Radwan MM, Wanas AS, van Antwerp J, Parcher JF, ElSohly MA, Khan IA. Decarboxylation study of Acidic cannabinoids: a Novel Approach using Ultra-high-performance Supercritical Fluid Chromatography/Photodiode array-Mass Spectrometry. Cannabis Cannabinoid Res. 2016;1:262–71.
doi: 10.1089/can.2016.0020
pubmed: 28861498
pmcid: 5549281
Dussy FE, Hamberg C, Luginbühl M, Schwerzmann T, Briellmann TA. Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products. Forensic Sci Int. 2005;149:3–10.
doi: 10.1016/j.forsciint.2004.05.015
pubmed: 15734104
Janssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP. Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays-and how this matters for the harm potential of seized drugs. Arch Toxicol. 2024. https://doi.org/10.1007/s00204-024-03769-4 .
Mardal M, Andreasen MF, Mollerup CB, Stockham P, Telving R, Thomaidis NS, Diamanti KS, Linnet K, Dalsgaard PW. HighResNPS.com: an online crowd-sourced HR-MS database for suspect and non-targeted screening of New Psychoactive substances. J Anal Toxicol. 2019;43:520–7.
doi: 10.1093/jat/bkz030
pubmed: 31095696
Chiang CH, Lee HH, Chen BH, Lin YC, Chao YY, Huang YL. Using ambient mass spectrometry and LC-MS/MS for the rapid detection and identification of multiple illicit street drugs. J Food Drug Anal. 2019;27:439–50.
doi: 10.1016/j.jfda.2018.11.003
pubmed: 30987715
Alves VL, Gonçalves JL, Aguiar J, Caldeira MJ, Teixeira HM, Câmara JS. Highly sensitive screening and analytical characterization of synthetic cannabinoids in nine different herbal mixtures. Anal Bioanal Chem. 2021;413:2257–73.
doi: 10.1007/s00216-021-03199-6
pubmed: 33575815
Ogata J, Uchiyama N, Kikura-Hanajiri R, Goda Y. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. Forensic Sci Int. 2013;227:33–41.
doi: 10.1016/j.forsciint.2012.09.006
pubmed: 23092848
Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, Beuerle T. Spice: a never ending story? Forensic Sci Int. 2009;191:58–63.
doi: 10.1016/j.forsciint.2009.06.008
pubmed: 19589652
Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. 2010;198:31–8.
doi: 10.1016/j.forsciint.2010.01.004
pubmed: 20117892
Moosmann B, Angerer V, Auwärter V. Inhomogeneities in herbal mixtures: a serious risk for consumers. Forensic Toxicol. 2015;33:54–60.
doi: 10.1007/s11419-014-0247-4
Moreno-Sanz G. Can you pass the Acid Test? Critical review and novel therapeutic perspectives of ∆(9)-Tetrahydrocannabinolic acid A. Cannabis Cannabinoid Res. 2016;1:124–30.
doi: 10.1089/can.2016.0008
pubmed: 28861488
pmcid: 5549534
Deng H. Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs. Ph.D. University of Connecticut; 2000.
Marusich JA, Wiley JL, Lefever TW, Patel PR, Thomas BF. Finding order in chemical chaos - continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology. 2018;134:73–81.
doi: 10.1016/j.neuropharm.2017.10.041
pubmed: 29113898
Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of First and Second Generation Legal Highs for Synthetic cannabinoids and Synthetic stimulants by Ultra-performance Liquid Chromatography and Time of Flight Mass Spectrometry. J Anal Toxicol. 2012;36:360–71.
doi: 10.1093/jat/bks047
pubmed: 22586208
Wouters E, Mogler L, Cannaert A, Auwärter V, Stove C. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine. Drug Test Anal. 2019;11:1183–91.
doi: 10.1002/dta.2607
pubmed: 31021521
Verougstraete N, Vandeputte MM, Lyphout C, Cannaert A, Hulpia F, Van Calenbergh S, Verstraete AG, Stove C. First Report on Brorphine: the next opioid on the Deadly New Psychoactive Substance Horizon? J Anal Toxicol. 2020;44:937–46.
doi: 10.1093/jat/bkaa094
Vandeputte MM, Verougstraete N, Walther D, Glatfelter GC, Malfliet J, Baumann MH, Verstraete AG, Stove CP. First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass. Arch Toxicol. 2022;96:1865–80.
doi: 10.1007/s00204-022-03294-2
pubmed: 35449307